FacebookTwitterGoogle+RedditEmail

Patient Front Groups Loot Medicare Dollars for Big Pharma

by MARTHA ROSENBERG

The Obama administration is finally addressing the expensive, dangerous and usually unnecessary psychiatric drugs that are footed by taxpayers in federal entitlement programs. It has proposed that insurers may limit Medicare coverage of certain classes of drugs that include Wellbutrin, Paxil and Prozac for depression and Abilify and Seroquel for schizophrenia.

How expensive are these drugs? 100 middle dose pills of the widely marketed Abilify cost as much as $1,644. 100 pills of Geodon are $958, Invega, $1,789, Risperdal, $953, Seroquel, $2,000 and Zyprexa, $1,680, if the brand name drugs are used, which drug company  lobbyists hope. Thanks to their lobbying, insurers have to pay “all or substantially all” of such depression and schizophrenia drug costs because the drugs enjoy “protected status” in the Medicare program. Such protected pills account for as much as 33 percent of total outpatient drug spending under Part D of Medicare, says the New York Times.

Not surprisingly, Big Pharma and its patient front groups are livid that the heisting of US taxpayers dollars could be curtailed. Abilify alone has earned over $4 billion a year! “The proposal undermines a key protection for some of the sickest, most vulnerable Medicare beneficiaries,” said Andrew Sperling, a lobbyist at the National Alliance on Mental Illness (NAMI) which is fighting the Obama proposal.

As much as 75 percent of NAMI’s donations come from drug companies says the New York Times and it has been investigated by Congress. Portraying itself as “patients,” NAMI also successfully fights states’ efforts to limit use of the most pricey Medicaid psychiatric drugs, in parallel lobbying. “Some of these medicines routinely top the list of the most expensive drugs that states buy for their poorest patients,” says the Times. NAMI is “hugely influential in many state capitols,” it adds.

The heart of Big Pharma and NAMI lobbying is making sure expensive drugs are on Medicare and Medicaid formularies and that doctors prescribe them first–before and instead of lower priced drugs. The expensive-drugs-first marketing is couched as “patient choice” or another “treatment option” by Pharma lobbyists as if there’s no difference between a $45 prescription and $450 prescription. Antipsychotic drugs work in different ways in the body explains Sperling and “You get much better outcomes when a doctor can work with patients to figure out which medications will work best for them.” Ka-ching.

The problem is newer, more expensive drugs are not necessarily better than older, less expensive drugs and they are often more dangerous. One chilling example is an estimated 15,000 elderly people die in nursing homes a year from inappropriately given antipsychotic medications, according to FDA drug reviewer David Graham, MD.  Pharma is aware of the profiteering and “laughing all the way to the bank,” Graham speculated.

Antipsychotics like Seroquel carry warnings that they cause death in elderly people who have dementia but are nevertheless in wide use in many geriatric, federally-supported facilities. So much for NAMI’s concern for “the sickest, most vulnerable Medicare beneficiaries.”

NAMI is not the only group to play on the public’s heart strings to keep drug revenues flowing. Pharma’s aggressive opioid lobby says patients with legitimate pain will suffer if drugs like Oxycontin, killing 17,000 Americans a year, are regulated. Similarly, if Abilify and Seroquel are regulated within Medicare, someone will suffer–Big Pharma.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

 

 

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
April 29, 2016
Friday - Sunday
Andrew Levine
What is the Democratic Party Good For? Absolutely Nothing
Roberto J. González – David Price
Anthropologists Marshalling History: the American Anthropological Association’s Vote on the Academic Boycott of Israeli Institutions
Robert Jacobs
Hanford, Not Fukushima, is the Big Radiological Threat to the West Coast
Ismael Hossein-Zadeh
US Presidential Election: Beyond Lesser Evilism
Dave Lindorff
The Push to Make Sanders the Green Party’s Candidate
Ian Fairlie
Chernobyl’s Ongoing Toll: 40,000 More Cancer Deaths?
Pete Dolack
Verizon Sticks it to its Workers Because $45 Billion isn’t Enough
Richard Falk
If Obama Visits Hiroshima
Margaret Kimberley
Dishonoring Harriet Tubman
Deepak Tripathi
The United States, Britain and the European Union
Peter Linebaugh
Marymount, Haymarket, Marikana: a Brief Note Towards ‘Completing’ May Day
Eva Golinger
My Country, My Love: a Conversation with Gerardo and Adriana of the Cuban Five
Moshe Adler
May Day: a Trade Agreement to Unite Third World and American Workers
Vijay Prashad
Political Violence in Honduras
Paul Krane
Where Gun Control Ought to Start: Disarming the Police
David Anderson
Al Jazeera America: Goodbye to All That Jazz
Rob Hager
Platform Perversity: More From the Campaign That Can’t Strategize
Pat Williams
FDR in Montana
Dave Marsh
Every Day I Read the Book (the Best Music Books of the Last Year)
David Rosen
Job Satisfaction Under Perpetual Stagnation
John Feffer
Big Oil isn’t Going Down Without a Fight
Murray Dobbin
The Canadian / Saudi Arms Deal: More Than Meets the Eye?
Gary Engler
The Devil Capitalism
Brian Cloughley
Is Washington Preparing for War Against Russia?
Manuel E. Yepe
The Big Lies and the Small Lies
Robert Fantina
Vice Presidents, Candidates and History
Mel Gurtov
Sanctions and Defiance in North Korea
Howard Lisnoff
Still the Litmus Test of Worth
Dean Baker
Big Business and the Overtime Rule: Irrational Complaints
Ulrich Heyden
Crimea as a Paradise for High-Class Tourism?
Ramzy Baroud
Did the Arabs Betray Palestine? – A Schism between the Ruling Classes and the Wider Society
Halyna Mokrushyna
The War on Ukrainian Scientists
Joseph Natoli
Who’s the Better Neoliberal?
Ron Jacobs
The Battle at Big Brown: Joe Allen’s The Package King
Wahid Azal
Class Struggle and Westoxication in Pahlavi Iran: a Review of the Iranian Series ‘Shahrzad’
David Crisp
After All These Years, Newspapers Still Needed
Graham Peebles
Hungry and Frightened: Famine in Ethiopia 2016
Robert Koehler
Opening the Closed Political Culture
Missy Comley Beattie
Waves of Nostalgia
Thomas Knapp
The Problem with Donald Trump’s Version of “America First”
Georgina Downs
Hillsborough and Beyond: Establishment Cover Ups, Lies & Corruption
Jeffrey St. Clair
Groove on the Tracks: the Magic Left Hand of Red Garland
Ben Debney
Kush Zombies: QELD’s Hat Tip to Old School Hip Hop
Charles R. Larson
Moby Dick on Steroids?
David Yearsley
Miles Davis: Ace of Baseness
FacebookTwitterGoogle+RedditEmail